Binds Expression Product Or Fragment Thereof Of Cancer-related Gene (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 424/138.1)
  • Patent number: 10975161
    Abstract: The disclosure relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: April 13, 2021
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Eleanora Balloi, Normann Goodwin, Brian McGuinness, Chris Rossant, Thomas Sandal, Lorraine Thompson
  • Patent number: 10961301
    Abstract: Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: March 30, 2021
    Assignees: Yale University, The Regents of the University of California, The United States Government Represented by the Department of Veterans Affairs
    Inventors: James E. Hansen, Peter M. Glazer, Richard H. Weisbart, Robert N. Nishimura, Grace Chan
  • Patent number: 10941204
    Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: March 9, 2021
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
  • Patent number: 10925867
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: February 23, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Christopher Lee Mulligan, Justin Blake Bartlett, Michael Darron Robbins
  • Patent number: 10894051
    Abstract: A method of treating metastatic cancer in a subject suffering from metastatic cancer includes administering an effective amount of a compound having a structure of Formula I, in particular a compound having a structure of Formula II, to the subject. Also, a method of inhibiting metastasis of cancer cells includes contacting the cancer cells with an effective amount of a compound having the structure of Formula I, in particular a compound having the structure of Formula II.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: January 19, 2021
    Assignee: City University of Hong Kong
    Inventor: Jianbo Yue
  • Patent number: 10828377
    Abstract: An object of the present invention is to provide a method for determining whether a subject suffers from malignant lymphoma or leukemia and an agent for treating and/or preventing the disease. The present invention relates to a method for assisting in determining whether a subject suffers from, or is likely to suffer from malignant lymphoma or leukemia, comprising: a detection step of detecting at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene; and a determination step of determining that the subject suffers from or is likely to suffer from the disease when at least one of the fusion mutations or the overexpression is detected. Moreover, the present invention relates to a pharmaceutical composition comprising a DUX4 inhibitor as an active ingredient, for treating and/or preventing malignant lymphoma or leukemia in a subject having a fusion mutation of a DUX4 gene and an IGH or IGL gene and/or overexpression of a DUX4 gene.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 10, 2020
    Assignees: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, AICHI PREFECTURE, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Hiroyuki Mano, Toshihide Ueno, Takahiko Yasuda, Masahito Kawazu, Fumihiko Hayakawa, Hitoshi Kiyoi, Shinobu Tsuzuki, Tomoki Naoe
  • Patent number: 10787641
    Abstract: The present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: September 29, 2020
    Assignee: Emory University
    Inventors: Young-sup Yoon, Hyun-Jai Cho
  • Patent number: 10774133
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 15, 2020
    Assignee: MedImmune Limited
    Inventors: Brian Lobo, Deborah Goldberg
  • Patent number: 10738282
    Abstract: The finding that phosphatidylserine (PtdSer) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (PLSCR1) activity prevents PtdSer externalization and enables prolonged protection of vector-transduced cells from phagocytosis. Methods of inhibiting a virus vector-induced inflammatory response in tissue, methods of prolonging virus vector encoded transgene expression, and methods of modulating an inflammatory response in tissue of a subject, by administering an inhibitor of PLSCR1 are described.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 11, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Axel Nimmerjahn, Charles L. Clark
  • Patent number: 10683348
    Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee, Patrick Koenig
  • Patent number: 10683328
    Abstract: The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: June 16, 2020
    Assignees: BIOMARCK PHARMACEUTICALS LTD., NORTH CAROLINA STATE UNIVERSITY
    Inventors: Indu Parikh, Kenneth B. Adler
  • Patent number: 10501555
    Abstract: The present invention refers to humanized anti-Trop-2 antibodies and their fragments, derivatives and conjugates that are able to recognise and bind with high affinity distinct regions of the Trop-2 molecule. The present invention also teaches the use of such antibodies and of pharmaceutical compositions thereof for diagnosis and therapy of human pathologies, in particular cancer.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 10, 2019
    Assignee: ABRUZZO THERANOSTIC S.R.L.
    Inventors: Emanuela Guerra, Saverio Alberti
  • Patent number: 10398688
    Abstract: The invention relates to a combination of an immunomodulatory imide drug (IMiD) and an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a subject. It further relates to an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a patient, wherein the patient is IMiD resistant. It further relates to a method of monitoring the efficacy of an IMiD treatment regimen by comparing the protein level of CD147 and/or MCT1 in samples obtained from a subject prior and during IMiD treatment.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: September 3, 2019
    Assignee: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MÜNCHEN
    Inventors: Florian Bassermann, Ruth Eichner, Vanesa Fernandez-Saiz
  • Patent number: 10392398
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: August 27, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • Patent number: 10378061
    Abstract: A method of predicting an effect of an anti-c-Met antibody and/or selecting a subject for application of an anti-c-Met antibody including measuring a level of the biomarker in a biological sample, is provided.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 13, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jongsuk Chung, Tae Jin Ahn, Dae-Soon Son, Eunjin Lee
  • Patent number: 10288621
    Abstract: A method to detect local antibodies such as antigen-specific IgE via a brush biopsy specimen of a mucosal surface of a subject is disclosed. The method is easily performed in an office setting on both adult and pediatric patients. Also disclosed is a brush device specially designed for harvesting materials from a mucosal surface such as the medial surface of the inferior turbinate.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: May 14, 2019
    Assignee: Cornell University
    Inventor: William Reisacher
  • Patent number: 10208357
    Abstract: The present invention relates to cell-based assays involving HER2. The assays use assay cells that are transfected with cassettes containing the HER2 gene of interest and measure the effect of mutations on the activity of HER2, and on their response to inhibitors.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: February 19, 2019
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventor: Yick Loi Raymond Yu
  • Patent number: 10139394
    Abstract: The present invention relates to a novel function of lysyl tRNA synthetase, that is, lysyl tRNA synthetase interacts with 67LR through translocation of KRS into plasma membrane, and so enhances tumor (or cancer) cell migration, thereby having an effect on cancer metastasis. More specifically, it relates to method for controlling cancer metastasis or cancer cell migration by modulating an cellular level of lysyl tRNA synthetase, an use of an expression vector comprising a construct inhibiting KRS expression for preventing or treating cancer, an use of an agent inhibiting KRS activity for preventing or treating cancer, a method for screening an agent which modulates cancer metastasis or cancer cell migration, a method for screening an agent inhibiting an interaction between KRS and 67LR. Accordingly, cancer metastasis and cancer cell migration may be controlled using the inventive KRS, further the cellular metabolism related to laminin receptor (67LR) of plasma membrane may be controlled.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 27, 2018
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Jin Woo Choi
  • Patent number: 10119122
    Abstract: The disclosure is concerned among others with means and methods for obtaining endothelial cells and to means and methods for in vitro cell culture comprising endothelial cells and pericytes and/or smooth muscle cells derived from the pericytes. The endothelial cells or the pericytes and/or smooth muscle cells, or both, are preferably derived from in vitro differentiated pluripotent stem cells.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: November 6, 2018
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Christine Lindsay Mummery, Valeriya Viktorovna Orlova
  • Patent number: 10112977
    Abstract: Provided are a synthetic peptide having a multinucleation-inducing activity that can cause multinucleation in a target cell, a multinucleation-inducing agent containing this peptide, and a multinucleation induction method that uses this peptide. The synthetic peptide provided by the present invention is an artificially synthesized peptide that contains (A) a membrane-permeable peptide sequence and (B) a multinucleation-inducing peptide sequence, and that can cause multinucleation in at least one type of eukaryotic cell of human origin or non-human mammal origin. The multinucleation-inducing peptide sequence is constituted of an amino acid sequence given by SEQ ID NO: 1 or SEQ ID NO: 2 or a modified amino acid sequence therefrom.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: October 30, 2018
    Assignees: Toagosei Co., Ltd., National University Corporation Nagoya University
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada
  • Patent number: 10030071
    Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: July 24, 2018
    Assignees: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.
    Inventors: Kazuhiro Morishita, Kazuko Kaneda, Yoshikazu Kurosawa, Gene Kurosawa, Katsuyuki Mitomo, Katsushi Kouda, Yoshinori Ukai
  • Patent number: 9969811
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: May 15, 2018
    Assignee: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Patent number: 9950077
    Abstract: The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: April 24, 2018
    Assignees: BIOALLIANCE C.V., ABGENOMICS INTERNATIONAL INC.
    Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang, Shu-Hua Lee, Yu-Ying Tsai, Feng-Lin Chiang, Li-An Hu
  • Patent number: 9932410
    Abstract: The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: April 3, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier, Universite Paris- Sud, Institut Regional du Cancer du Montpellier, Ecole Normale Superieure de Cachan
    Inventors: Marie-Alix Poul, Mariane Le Gall, Ronan Crepin
  • Patent number: 9901594
    Abstract: Pharmaceutical compositions containing a combination of NPM inhibitor and anti-cancer agent are disclosed. Methods of inhibiting or reducing the growth of cancer cells in a subject, by administering an effective amount of nucleophosmin (NPM) inhibitor and one or more anti-cancer agents, whereby the symptoms and signs of cancer in the subject are reduced are also provided.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: February 27, 2018
    Assignees: CHANG GUNG MEMORIAL HOSPITAL
    Inventor: Sen-yung Hsieh
  • Patent number: 9828643
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • Patent number: 9828424
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 9815904
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: November 14, 2017
    Assignee: Genetech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Patent number: 9789203
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 17, 2017
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Cohen, Christie P. Fanton, Catrin Finner, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Patent number: 9745377
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: August 29, 2017
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga
  • Patent number: 9730926
    Abstract: Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: August 15, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Powei Lin, Kwang Ho Cheong, Young Jun Koh, Jae-woong Hwang, Seung Hyun Lee, Jung Wook Lee
  • Patent number: 9717715
    Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: August 1, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Hyun Lee, Geun Woong Kim, Kyung Ah Kim, Hye Won Park, Ho Yeong Song, Young Mi Oh, Saet Byoul Lee, Ji Min Lee, Kwang Ho Cheong, Yun Ju Jeong, Mi Young Cho, Jae Hyun Choi, Yun Jeong Song, Yoon Aa Choi
  • Patent number: 9707250
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 18, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE BORDEAUX, Université d' Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre Régional de Lutte Contre le Cancer, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Arnaud Gissot, Palma Rocchi, Julie Acunzo
  • Patent number: 9701962
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 11, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE BORDEAUX, UNIVERSITE D 'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • Patent number: 9701740
    Abstract: Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: July 11, 2017
    Assignees: YALE UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The United States of America represented by the Department of Veterans Affairs
    Inventors: James E. Hansen, Peter M. Glazer, Richard H. Weisbart, Robert N. Nishimura, Grace Chan
  • Patent number: 9684000
    Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 20, 2017
    Assignee: GENENTECH, INC.
    Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
  • Patent number: 9676865
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: June 13, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin L. Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Patent number: 9589100
    Abstract: A method of computing the risk profile of a neoplastic tissue in a patient is disclosed. The method includes the steps of (a) processing a sample of tumor tissue or cancer cells from the patient in a form suitable for visualization and demarcation of cell nuclei, individually distinguishable centrosomes (iCTRs) and megacentrosomes (mCTRs) in a region of interest (ROI) defined by a plurality of cell nuclei; (b) determining the numbers of iCTRs and mCTRs associated with each cell nucleus in the ROI; (c) determining the volume of each iCTR and mCTR in the ROI; and (d) calculating one or more centrosome amplification scores (CASs) values for the sample based on steps (b) and (c), wherein the one or more CASs indicate the severity of centrosome amplification, the frequency of centrosome amplification, or both, and wherein the one or more scores provide a measure of a level of risk and/or a prognosis associated with the neoplastic tissue.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: March 7, 2017
    Assignee: NOVAZOI THERANOSTICS
    Inventors: Ritu Aneja, Padmashree C. G. Rida
  • Patent number: 9546218
    Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: January 17, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Gavin Thurston
  • Patent number: 9527907
    Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, and/or for use in delivery to the neovasculature of endometriotic tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, psoriatic arthritis or psoriasis, and/or for use in delivery to the neovasculature of endometriotic, psoriatic arthritic or psoriatic tissue of a molecule conjugated to the specific binding member.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: December 27, 2016
    Assignee: Philogen S.P.A.
    Inventor: Kathrin Schwager
  • Patent number: 9511085
    Abstract: The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intracellular metabolism related to 67LR.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: December 6, 2016
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Jin Woo Choi
  • Patent number: 9487591
    Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: November 8, 2016
    Assignees: KYOWA HAKKO KIRIN CO., LTD, Kyushu University, National University Corporation
    Inventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
  • Patent number: 9448239
    Abstract: The present invention provides and includes monoclonal antibodies specific or preferentially selective for PCBP-1 antigens, as well as methods utilizing these antibodies to determine the severity of breast cancer in a patient.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: September 20, 2016
    Assignee: ALPER BIOTECH LLC
    Inventor: •gze Alper
  • Patent number: 9417243
    Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: August 16, 2016
    Assignee: Biocare Medical, LLC
    Inventors: Weimin Qi, David Tacha
  • Patent number: 9399779
    Abstract: Provided are alternative splicing constructs and methods for their use. In particular, CD44 based alternative splicing constructs are provided that include CD44 exon 5. These alternative splicing constructs are useful in high-throughput assays for testing the effects of compounds on splicing and for achieving targeted cell death.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: July 26, 2016
    Assignee: The Corporation of Mercer University
    Inventors: Dayle A. Daines, Robert J. McKallip
  • Patent number: 9340615
    Abstract: An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the present invention have high antitumor activity, and are useful as agents for decreasing the AXL expression level, antitumor agents, and diagnostic agents for cancer.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: May 17, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsuhiko Maeda, Hajime Miyamoto, Taichi Kuramochi, Atsushi Matsuo, Tomoyuki Igawa, Hirotake Shiraiwa, Hiroyuki Tsunoda, Tatsuhiko Tachibana
  • Patent number: 9316654
    Abstract: We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 19, 2016
    Assignee: Agency For Science, Technology and Research (A*STAR)
    Inventors: Wanjin Hong, Siew Wee Chan
  • Patent number: 9308278
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 12, 2016
    Assignee: Agensys, Inc.
    Inventors: Michael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
  • Patent number: 9249188
    Abstract: The present Invention relates to nanopeptides isolated from mammalian colostrums with vaccine like antiviral and immunodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: February 2, 2016
    Inventor: Pawan Saharan
  • Patent number: RE45968
    Abstract: It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 12, 2016
    Assignee: SIGMA TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Olga Minenkova, Emiliano Pavoni